There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN – Research Report) and Arcellx Inc (ACLX – Research Report) with bullish sentiments.
Don’t Miss Our End of Quarter Offers:
Illumina (ILMN)
Argus Research analyst Jasper Hellweg maintained a Buy rating on Illumina on March 28 and set a price target of $100.00. The company’s shares closed last Monday at $78.76.
According to TipRanks.com, Hellweg is a 4-star analyst with an average return of 6.2% and a 54.2% success rate. Hellweg covers the Healthcare sector, focusing on stocks such as Baxter International, Teva Pharmaceutical, and United Therapeutics.
Currently, the analyst consensus on Illumina is a Moderate Buy with an average price target of $128.56, a 61.9% upside from current levels. In a report issued on March 28, Guggenheim also maintained a Buy rating on the stock with a $122.00 price target.
See the top stocks recommended by analysts >>
Arcellx Inc (ACLX)
In a report issued on March 26, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcellx Inc, with a price target of $104.00. The company’s shares closed last Monday at $62.71.
According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.4% and a 30.8% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Century Therapeutics, and Bolt Biotherapeutics.
Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $117.15, a 78.5% upside from current levels. In a report issued on March 14, Barclays also maintained a Buy rating on the stock with a $115.00 price target.
Read More on ILMN: